Considerable data support the hypothesis that mitochondrial abnormalities link gene defects and/or environmental insults to the neurodegenerative process. The interaction of oxidants with calcium and the mitochondrial enzymes of the tricarboxylic acid cycle are central to that relationship. Abnormalities that were discovered in brains or fibroblasts from patients with Alzheimer's disease (AD) have been modeled in vitro and in vivo to assess their pathophysiological importance and to determine how they might be reversed. The conclusions are consistent with the hypothesis that the AD-related abnormalities result from oxidative stress. The selection of compounds for reversal is complex because the actions of the relevant compounds vary under different conditions, such as cell redox states and acute versus chronic changes. However, the models that have been developed are useful for testing the effectiveness of the potential medications. The results suggest that the reversal of mitochondrial deficits and a reduction in oxidative stress will reduce clinical and pathological changes and benefit patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2744687 | PMC |
http://dx.doi.org/10.1196/annals.1427.038 | DOI Listing |
Age Ageing
January 2025
Centre for Psychiatry and Mental Health, Wolfson Institute of Population Health, Queen Mary University of London, London, E13 8SP, United Kingdom of Great Britain and Northern Ireland.
Background: Behavioural and psychological symptoms of dementia (BPSD) can complicate acute hospital care, but evidence on BPSD in this setting is heterogeneous.
Objective: To determine the prevalence of BPSD in acute hospitals and explore related risk factors, treatments, and outcomes (PROSPERO: CRD42023406294).
Methods: We conducted a systematic review and meta-analysis by searching Cochrane Library, MEDLINE, and PsycINFO for studies on BPSD prevalence among older people with dementia during their acute hospital admissions (up to 5 March 2024).
Brain
January 2025
Reina Sofia Alzheimer Centre, CIEN Foundation, ISCIII, Madrid, Spain.
Lewy body (LB) pathology is present as a co-pathology in approximately 50% of Alzheimer's disease (AD) dementia patients and may even represent the main neuropathologic substrate in a subset of patients with amnestic impairments. However, the degree to which LB pathology affects the neurodegenerative course and clinical phenotype in amnestic patients is not well understood. Recently developed α-synuclein seed amplification assays (αSyn-SAAs) provide a unique opportunity for further investigating the complex interplay between AD and LB pathology in shaping heterogeneous regional neurodegeneration patterns and clinical trajectories among amnestic patients.
View Article and Find Full Text PDFGeroscience
January 2025
Institute of Biomedical Engineering, School of Life Sciences, Shanghai University, Shanghai, 200444, China.
Brain network dynamics have been extensively explored in patients with subjective cognitive decline (SCD). However, these studies are susceptible to individual differences, scanning parameters, and other confounding factors. Therefore, how to reveal subtle SCD-related subtle changes remains unclear.
View Article and Find Full Text PDFEur J Nucl Med Mol Imaging
January 2025
Reina Sofia Alzheimer Center, CIEN Foundation, ISCIII, Madrid, Spain.
Purpose: Imaging biomarkers bear great promise for improving the diagnosis and prognosis of cognitive impairment in Parkinson's disease (PD). We compared the ability of three commonly used neuroimaging modalities to detect cortical changes in PD patients with mild cognitive impairment (PD-MCI) and dementia (PDD).
Methods: 53 cognitively normal PD patients (PD-CN), 32 PD-MCI, and 35 PDD underwent concurrent structural MRI (sMRI), diffusion-weighted MRI (dMRI), and [F]FDG PET.
Alzheimers Dement
January 2025
Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA.
Introduction: This study investigates the inter-related roles of hippocampal neuronal loss (HNL), limbic-predominant age-related TAR-DNA binding protein of 43 kDa (TDP-43) encephalopathy neuropathologic changes (LATE-NC), and Alzheimer's disease neuropathologic changes (ADNC) on cognitive decline.
Methods: Participants underwent annual cognitive testing and autopsy. HNL, ADNC, LATE-NC, and other age-related pathologies were evaluated.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!